Compare Merck & Co., Inc. (MRK) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Public Storage — how do they compare? Merck & Co., Inc. trades at $142.16 (market cap $352.29B), while Public Storage trades at $285.55 (market cap $52.69B). The key difference: Merck & Co., Inc. is far larger — about 6.7× Public Storage's market cap, and Public Storage pays the higher dividend (4.26%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Public Storage for 130 Days on average.
| MRK | PSA | |
|---|---|---|
Market Cap | $352.29B | $52.69B |
Volume | 6,348,796 | 975,662 |
Sector | Health | Real Estate |
52-Week High | $156.43 | $330.47 |
52-Week Low | $82.49 | $258.44 |
Typical Hold Time | 98 Days | 130 Days |
Enterprise Value | $399.05B | $66.96B |
Dividend Yield | 2.38% | 4.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
Public Storage (PSA) trades at $285.52, down 0.12% on the day, with a bearish technical signal. The stock shows strong profitability with a 41.8% net income margin and has beaten earnings estimates for three consecutive quarters. Recent corporate actions include the completion of the Public Storage Canada acquisition and a $3.00 dividend declared for payment in October 2026. Analyst consensus is a Buy with a $328.33 price target, implying potential upside.
The outlook is mixed; strong fundamentals and analyst support suggest long-term value, but near-term technical weakness and fluctuating cash flows pose risks. Investors should weigh the high valuation multiples against the company's operational resilience and dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
